Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
European Medical Journal12d
UK Chikungunya vaccine approval in sight for Bavarian Nordic
The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.
PharmiWeb13d
Global Attenuated Vaccines Market Poised for Significant Growth, Expected to Reach USD 9,693.9 Million by 2034 at a CAGR of 6.8% | FMI
The global attenuated vaccines market is set for remarkable expansion, with sales projected to surge from USD 5,068.2 million in 2024 to an estimated USD 9,693.9 million by 2034. This growth ...
Le Lézard15d
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980 ...
emjreviews.com15d
Spotlight: February 2025
The UK’s Medicines and Healthcare products Regulatory Agency approves the world’s first chikungunya vaccine, providing new protection against the mosquito-borne virus as cases surge in endemic regions ...
BioSpace17d
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...
ETF Daily News17d
Valneva’s (VALN) Buy Rating Reaffirmed at HC Wainwright
The company has a market cap of $548.51 million, a PE ratio of -51.92 and a beta of 1.98. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78 ...
Finanznachrichten19d
Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ
Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, "Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's ...